Model describing the relationship between pharmacokinetics and hematologic toxicity of the epirubicin-docetaxel regimen in breast cancer patients
M Sandstrom - Journal of clinical oncology, 2005 - ascopubs.org
Purpose The aims of the present study were (1) to characterize the pharmacokinetics of both
component drugs and (2) to describe the relationship between the pharmacokinetics and the …
component drugs and (2) to describe the relationship between the pharmacokinetics and the …
[HTML][HTML] Model describing the relations between pharmacokinetics and hematological toxicity of the epirubicin-docetaxel regimen in breast cancer
M Sandström, H Lindman, P Nygren… - Journal of Clinical …, 2005 - diva-portal.org
PURPOSE: The aims of the present study were (1) to characterize the pharmacokinetics of
both component drugs and (2) to describe the relationship between the pharmacokinetics …
both component drugs and (2) to describe the relationship between the pharmacokinetics …
[PDF][PDF] Model Describing the Relationship Between Pharmacokinetics and Hematologic Toxicity of the Epirubicin-Docetaxel Regimen in Breast Cancer Patients
M Sandström, H Lindman, P Nygren, E Lidbrink… - J Clin Oncol, 2005 - Citeseer
Purpose The aims of the present study were (1) to characterize the pharmacokinetics of both
component drugs and (2) to describe the relationship between the pharmacokinetics and the …
component drugs and (2) to describe the relationship between the pharmacokinetics and the …
Model describing the relationship between pharmacokinetics and hematologic toxicity of the epirubicin-docetaxel regimen in breast cancer patients.
M Sandström, H Lindman, P Nygren… - Journal of Clinical …, 2004 - europepmc.org
Purpose The aims of the present study were (1) to characterize the pharmacokinetics of both
component drugs and (2) to describe the relationship between the pharmacokinetics and the …
component drugs and (2) to describe the relationship between the pharmacokinetics and the …
Model describing the relationship between pharmacokinetics and hematologic toxicity of the epirubicin-docetaxel regimen in breast cancer patients
M Sandström, H Lindman, P Nygren… - Journal of clinical …, 2005 - pubmed.ncbi.nlm.nih.gov
Purpose The aims of the present study were (1) to characterize the pharmacokinetics of both
component drugs and (2) to describe the relationship between the pharmacokinetics and the …
component drugs and (2) to describe the relationship between the pharmacokinetics and the …
Model Describing the Relationship Between Pharmacokinetics and Hematologic Toxicity of the Epirubicin-Docetaxel Regimen in Breast Cancer Patients
M Sandström, H Lindman, P Nygren… - Journal of Clinical …, 2005 - cir.nii.ac.jp
抄録< jats: sec>< jats: title> Purpose</jats: title>< jats: p> The aims of the present study were
(1) to characterize the pharmacokinetics of both component drugs and (2) to describe the …
(1) to characterize the pharmacokinetics of both component drugs and (2) to describe the …
[引用][C] Model describing the relationship between pharmacokinetics and hematologic toxicity of the epirubicin-docetaxel regimen in breast cancer patients
M SANDSTRÖM, H LINDMAN… - Journal of clinical …, 2005 - pascal-francis.inist.fr
Model describing the relationship between pharmacokinetics and hematologic toxicity of the
epirubicin-docetaxel regimen in breast cancer patients CNRS Inist Pascal-Francis CNRS …
epirubicin-docetaxel regimen in breast cancer patients CNRS Inist Pascal-Francis CNRS …
[引用][C] Model describing the relationship between pharmacokinetics and hematologic toxicity of the epirubicin-docetaxel regimen in breast cancer patients.
M Sandström, H Lindman, P Nygren, E Lidbrink… - J Clin Oncol, 2005 - diva-portal.org